Biomyf-S (Mycophenolate sodium (MPS)) is an enteric coated, delayed release monosodium salt of Mycophenolate Acid (MPA).
Mycophenolate sodium (MPS) is approved for the prophylaxis of organ rejection in patients receiving allogeneic renal transplants, administered in combination with cyclosporine and corticosteroids.
MPS was originally developed in an attempt to reduce the rate of gastrointestinal adverse events (GI AEs) experienced when MMF was administered as part of an immunosuppressive regimen.
|Product||Active Ingredient(s)||Strength||Features||Dosage Form|
• Biomyf-S reduces the incidence of gastritis
• Biomyf-S significantly reduces the risk of graft loss and healthcare cost
• Biomyf-S has improved GI tolerability
• Biomyf-S improves patient compliance